Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 67 of 693 for:    CARBON DIOXIDE AND arterial

Effects of PEEP on Parameters of Tissue Perfusion in Patients Post Cardiac Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03753022
Recruitment Status : Active, not recruiting
First Posted : November 26, 2018
Last Update Posted : November 29, 2018
Sponsor:
Collaborator:
Vanessa Marques Ferreira
Information provided by (Responsible Party):
Solange Guizilini, Federal University of São Paulo

Brief Summary:

Pulmonary dysfunction is a condition inherent in cardiac surgery because of various interventions, such as general anesthesia, a median sternotomy, cardiopulmonary bypass and establishment of internal thoracic artery dissection.

In situations when there is a deterioration in oxygenation, increased positive pressure on the airways end pressure (PEEP) can be used as therapeutic mode by reversing severe hypoxemia resulting pulmonary shunt. But the use of PEEP has been associated to reduced cardiac output, due mainly to decrease systemic venous return consequent to increased intrathoracic pressure, and thus might reduce tissue oxygenation. Moreover, the increased transpulmonary gradient may also impair right ventricular ejection exacerbating the hemodynamic consequences in some patients, which in clinical practice this diagnosis may be difficult to perform.

In hypovolemic patients or those with cardiac changes may become even more pronounced, resulting in accentuation of low flow and systemic hypotension entailing changes in markers of tissue perfusion commonly measured by venous saturation central difference venoarterial carbon dioxide and lactate. The hypothesis of the investigators is that PEEP of 10 cmH2O and 15 cmH2O can be applied to reverse lung damage in patients in the immediate postoperative myocardial revascularization without repercussion tissue importantly in markers of tissue perfusion.

The objective is to evaluate the effects of different optimization levels of PEEP on gas exchange and influences the tissue perfusion after coronary artery bypass graft surgery.


Condition or disease Intervention/treatment Phase
Coronary Artery Disease Coronary Artery Bypass Grafting Acute Lung Injury Other: Group G5 Other: Group G10 Other: Group G15 Not Applicable

Detailed Description:
This is a prospective, randomized study and will be performed on patients who accept coronary artery bypass grafting with cardiopulmonary bypass, the conscious openness to participate in the study. Age, sex, body mass index (BMI), smoking habits, diagnosis, additional diseases, drugs used, surgery, intervention, peroperative supportive treatments, left ventricular ejection fraction, post operative blood and cardiopulmonary bypass (CPB) time (min), cross clamp time (min), duration of operation, postoperative extubation period, intensive care day of hospitalization, day of hospitalization will be recorded.The study was planned in 3 groups. Group G5 (control group: no changes will be made to the value of PEEP). Group G10 [after 30 minutes of admission (time 0) the PEEP will be raised to 10 cmH2O (time1) for 30 minutes and then returned to 5 cmH2O (time 2)]. Group G15 [after 30 minutes of admission (time 0) the PEEP will be raised to 15 cmH2O (time 1) for 30 minutes and then returned to 5 cm H2O (time 2)]. At each time of protocol (0, 1 and 2) will be collected: arterial blood gas measurements (partial pressure of arterial oxygen [PaO2] and partial pressure of carbon dioxide ([PaCO2]), the ratio between the partial oxygen pressure, inspired oxygen fraction (PaO2/FiO2) and pH. Also, will be performed parameters of tissue perfusion: central venous oxygen saturation ([SVO2]), arterial blood lactate, venoarterial CO2 difference ([Dif VA CO2]) and vital signs. In all other respects, treatment will follow the standard of care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 125 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The study was planned in 3 groups. Group G5 (control group: no changes will be made to the value of PEEP). Group G10 [after 30 minutes of admission (time 0) the PEEP will be raised to 10 cmH2O (time1) for 30 minutes and then returned to 5 cm H2O (time 2)]. Group G15 [after 30 minutes of admission (time 0) the PEEP will be raised to 15 cmH2O (time 1) for 30 minutes and then returned to 5 cm H2O (time 2)].
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of PEEP on Parameters of Tissue Perfusion and Clinical Outcomes After Coronary Artery Bypass Graft Surgery - a Randomized Clinical Trial
Actual Study Start Date : January 2012
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019


Arm Intervention/treatment
Sham Comparator: Group G5
Patients submitted to CABG and peep 5
Other: Group G5
Submitted to peep 5

Experimental: Group G10
Patients submitted to CABG and peep 10
Other: Group G10
Submitted to peep 10

Experimental: Group G15
Patients submitted to CABG and peep 15
Other: Group G15
Submitted to peep 15




Primary Outcome Measures :
  1. Pulmonary events [ Time Frame: Through study completion, an average of 24 hours after surgery ]
    Pleural effusion was considered relevant when exceeding the phrenicocostal angle and fluid drainage was monitored hourly. Atelectasis was acknowledged when a clear atelectasis radiologic shadow exceeded 15 mm in width, with linear atelectasis

  2. Arterial oxygenation [ Time Frame: Immediately after arrival at the intensive care unit until the end of protocol (around 5 hours) ]
    arterial blood gas measurements (partial pressure of arterial oxygen [PaO2]

  3. Tissue oxygenation [ Time Frame: Immediately after arrival at the intensive care unit until the end of protocol (around 5 hours) ]
    (central venous oxygen saturation , arterial blood lactate and venoarterial CO2 difference


Secondary Outcome Measures :
  1. Length of intensive care unit (ICU) stay [ Time Frame: From the day of surgery up to ICU discharge, maximum censoring at day 28 after surgery ] ]
    Days since surgery until ICU discharge

  2. Length of Hospital Stay [ Time Frame: From the day of surgery up to Hospital discharge, maximum censoring at day 28 after surgery ] ]
    Days since surgery until Hospital discharge

  3. Duration of mechanical ventilation [ Time Frame: Through study completion, an average of 24 hours after surgery ]
    Hours since surgery until extubation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • elective and isolated CABG, ejection fraction greater than 40%

Exclusion Criteria:

  • patients with a diagnosis of pulmonary disease, emergency surgery and mechanical ventilation prior to surgery.

Postoperative patients who had radiological abnormalities suggestive of pneumothorax, atrial or ventricular arrhythmias, electrical ischemic changes on ECG, pulse pressure variation of more than 13, hemodynamic instability characterized by mean arterial pressure less than 60 mmHg, nor epinephrine greater than 0.5 mcg/Kg/ min and the presence of increased bleeding through the drains (greater than 2 ml \ kg \ h) the protocol was discontinued and the patient excluded from the study.


Layout table for additonal information
Responsible Party: Solange Guizilini, Principal Investigator, Federal University of São Paulo
ClinicalTrials.gov Identifier: NCT03753022    
Other Study ID Numbers: 89704818.6.0000.5505
First Posted: November 26, 2018    Key Record Dates
Last Update Posted: November 29, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Solange Guizilini, Federal University of São Paulo:
Acute Lung Injury
postoperative of cardiac surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Arterial Occlusive Diseases
Lung Injury
Acute Lung Injury
Respiratory Distress Syndrome, Adult
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Vascular Diseases
Lung Diseases
Respiratory Tract Diseases
Thoracic Injuries
Wounds and Injuries
Respiration Disorders